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To investigate the usefulness of serum cytokine dosage in the clinical management of cystic echinococcosis (CE), we analyzed
serum levels of Th1 and Th2 cytokines in patients with hepatic CE in diﬀerent cyst stages, CE1-2 (active), CE3a-3b (transitional),
and CE4-5 (inactive). Ex vivo assessment of Th1 (IFN-γ) and Th2 (IL-4, IL-13, and IL-10) cytokines in sera was carried out using
ELISA. IL-10 was undetectable in all serum samples of patients and controls, while a few sera contained measurable amounts
of IFN-γ, IL-4, and IL-13. No statistically signiﬁcant diﬀerence was found between the percentages of positive samples for each
cytokine and the diﬀerent groups analyzed (patients/controls, stage, number, location, and size of the cyst, serology, and sex of
patients), with the exception of the association of IL-4 and IL-13 with the cyst stage. Overall, this investigation showed many limits
of serum cytokine dosage as a marker of biological activity of echinococcal cysts. Because of low sensitivity and lack of speciﬁcity
of this test, we believe that other ways to evaluate ex vivo biological activity of the cysts should be explored.
1.Introduction
Cystic echinococcosis (CE) is a chronic infection caused by
the tapeworm Echinococcus granulosus. In humans, the larval
stage of the parasite can develop and form cysts in almost
any organ, especially the liver and the lungs [1]. Diagnosis
and clinical decision making of CE are currently based on
imaging techniques, mainly ultrasound (US) and, to a lesser
extent, on serological techniques.
To date, serology is not standardized, and speciﬁc anti
bodies may persist for a long time, even after complete
surgical removal of the cyst [2, 3]. Furthermore, biological
activity of transitional cysts does not always match the US
appearance of the echinococcal cyst [4]. As a consequence,
cyst progression towards either inactivation or chroniciza-
tion can be assessed only by changes in US appearance of the
cyst and, to a lesser extent, by variation in antibody titers,
which is demonstrated only over long-term followup, thus
making serology less useful than US [5, 6].
To evaluate the biological activity of the cyst as a tool for
clinical decision making, in the last decade several studies
have tried to look for markers of the immune response
against Echinococcus granulosus. Some in vitro studies,
investigating cytokine production from peripheral blood
mononuclearcellsofCEpatients,demonstratedthepresence
of both Th1 and Th2 response against the parasite. During
chronicization of the infection, the more permissive Th2
response predominates in patients with active (or not cured)
cysts over the parasite-damaging Th1 response which, on the
contrary, is more active in patients with inactive (or cured)
cysts [7–10].2 Clinical and Developmental Immunology
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Figure 1: WHO-IWGE ultrasound classiﬁcation of echinococcal cysts.
Other ex vivo studies, which detected cytokines in sera
of CE patients, conﬁrmed the association between cytokine
production and outcome of the disease. Rigano et al.
reported a higher serum level of Interleukin-4 (IL-4) and IL-
10 in patients who did not respond to therapy compared
to those who responded; Bayraktar et al. showed higher
concentrations of IL-2, IL-4, and IL-10 in CE patients before
treatment compared to those who were treated and to
healthy controls; Mezioug and Touil-Boukoﬀa observed the
coexistence of elevated levels of Interferon-γ (IFN-γ), IL-12,
IL-16, IL-18, IL-4, IL-5, IL-10, and IL-13 in most sera of CE
patients compared to healthy controls [11–13].
Although these studies showed an association between
serum cytokine concentrations and active CE, in a recent
studywecouldnotconﬁrmsuchassociationforallcytokines,
as only a subgroup of CE patients with transitional cysts
showed increased IL-4 levels compared to other subgroups
andnegativecontrols[14].Additionally,thesestudiesdidnot
stratify patients according to the diﬀerent cystic stages at US,
which have been shown to correlate well with the biological
activity of the cysts, with the exception of transitional stages
[4, 15].
In this study, we analyzed serum levels of IFN-γ,I L - 4 ,
IL-13, and IL-10 in patients with hepatic CE in diﬀerent
US stages, to evaluate ex vivo the association of cytokine
productionandthestageoftheinfection.Asecondaimofthe
study was to assess whether serum cytokine dosage, which
could be easily implemented in a clinical setting, can reliably
assess the biological activity of CE cysts.
2.MaterialsandMethods
2.1. Subjects and Serum Samples. Serum samples were
obtained from 53 CE patients seen at the Department
of Infectious Diseases of the IRCCS San Matteo Hospital
Foundation in Pavia, Italy, and from 20 healthy controls.
The study protocol was approved by the ethical committee of
our institution, and all subjects gave their informed written
consent. Diagnosis of CE was made by ultrasound and
serological assays, and patients were selected according to
these inclusion criteria: (i) presence of at least one CE cyst
localizedtotheliver,(ii)no previoussurgeryforCE,and(iii)
no albendazole (ABZ) treatment or ABZ discontinuation at
least 24 months before the time of serum collection. The
control group was constituted by people for whom CE could
be excluded by both abdominal US and serological assays.
Serum samples were collected during a period of two years
(from March 2009 to March 2011) and stored at −80◦C until
assayed.
2.2. Ultrasound. All patients and controls were examined by
a clinician with long-standing experience in US and clinical
management of CE (EB) using a commercially available US
scanner with 3.5–5MHz convex probes (Aloka ProSound
ALPHA 10, Tokyo, Japan). For each patient, number,
stage, size and location of the cysts were reported. Cysts
were classiﬁed according to the World Health Organization
Informal Working Group on Echinococcosis (WHO-IWGE)
standardized US classiﬁcation for CE [16]( Figure 1)a sC E 1
and CE2 (active), CE3 (transitional), and CE4 and CE5
(inactive). Transitional CE3 cysts were further divided into
2 subgroups, CE3a and CE3b, based on their diﬀerence in
response to nonsurgical treatments and biological activity
[17]. Patients having multiple cysts were classiﬁed according
to the more active stage, in accordance with the results of
Hosch et al. [4]. Cyst size was reported as small, medium
or large, if the greatest cyst diameter was lower than 5cm,
between5and10cm,orgreaterthan10cm,respectively.Cyst
location in the liver was classiﬁed as being in the right, left,
or fourth segment.
2.3. Serology. All patients and controls were tested for anti-
Echinococcus antibodies by IgG enzyme-linked immunosor-
bent assay (ELISA, Cypress Diagnostic, Langdorp, Belgium)
and indirect hemagglutination (IHA, Cellognost Echinococ-
cosis; Dade Behring, Newark, USA) by the Laboratory of
Parasitology of our hospital. All controls and patients visited
were tested for IgG western blot (Echinococcus western blot
IgG, LDBIO, Lyon, France) during their ﬁrst visit at our
clinic. ELISA was considered positive if optical density was
greater than 1.1, while IHA tested positive for dilution
greater than 1/64. Serology was deﬁned as either positive or
negative, if both ELISA and IHA tested either positive or
negative respectively, and, if necessary, were conﬁrmed by
WB; serology was deﬁned as doubtful if one test was not
congruent with the other one(s).
2.4. Cytokine Assays. Serum concentrations of IFN-γ,I L - 4 ,
IL-13, and IL-10 were determined by ELISA commercial kits
(human IFN-γ, IL-4, and IL-10 high-sensitivity ELISA kitsClinical and Developmental Immunology 3
Table 1: Distribution of positive samples for IFN-γ,I L - 4 ,a n dI L - 1 3i nt h ed i ﬀerent groups analyzed (patients/controls, stage, number,
location, and size of the cyst, serology, and sex of patients). ∗Diﬀerence statistically signiﬁcant (P value < 0.05); the remaining diﬀerences
are not signiﬁcant.
Group Total IFN-γ positive IL-4 positive IL-13 positive
no. no. % no. % no. %
Total subjects 73 13 17.8 12 16.4 10 13.7
C o n t r o l s 2 052 552 521 0
Patients 53 8 15.1 7 13.2 8 15.1
Cyst stage
C E 1 - 2 5001 2 0
∗ 12 0
∗
CE3a 8 3 37.5 4 50 3 37.5
C E 3 b 2 042 01 5 0 0
C E 4 - 5 2 0 15154 2 0
Cyst number
1 4 67 1 5 . 2 61 361 3
2 7 1 14.3 1 14.3 2 28.6
Cyst liver location
Right segment 41 6 14.6 7 17.1 6 14.6
L e f t s e g m e n t 5 12 00 0 0 0
IV segment 7 1 14.3 0 0 2 28.6
Cyst size
Small 17 1 5.9 2 11.8 1 5.9
Medium 27 5 18.5 4 14.8 6 22.2
Large 9 2 22.2 1 11.1 1 11.1
Serology
Positive 29 6 20.7 6 20.7 4 13.8
Negative 19 2 10.5 0 0 2 10.5
D o u b t f u l 5001 2 0 2 4 0
Sex
M a l e 2 541 652 041 6
Female 28 4 14.3 2 7.1 4 14.3
and human IL-13 ELISA kit, Gen-Probe Diaclone, France)
according to the manufacturer’s instructions. All tests were
performed in duplicate. The ranges of the sensitivity stan-
dard curve of the ELISA kits were 0.78–25pg/mL for IFN-γ,
0.31–10pg/mLforIL-4,3.12–100pg/mLforIL-13,and1.56–
50pg/mL for IL-10.
2.5. Statistical Analysis. Diﬀerences in percentages of pa-
tients and controls with detectable levels of each cytokine
were assessed by Fisher’s exact test. The same test was
applied to assess any associations between cytokines and
stage, number, location, and size of the cysts, serology, and
sex of patients. A P value of less than 0.05 was considered
statistically signiﬁcant, and all tests were two sided. Data
analysis was performed with the STATA statistical package
(Ver. 10.0, 2009, Stata Corporation, College Station, TX,
USA).
3. Results
T h er e s u l t sa r es u m m a r i z e di nTable 1.
3.1. Subjects. This study included 73 subjects, 53 of whom
were patients with liver CE cysts in diﬀerent US stages, while
20 were healthy controls; in the control group CE could be
excluded by both abdominal US and serological assays that
tested negative. Of the 53 patients, 25 (47.2%) were males
and 28 (52.8%) were females. Forty-six (86.8%) harbored
one cyst each, while 7 (13.2%) harbored two cysts each. Five
had active CE1-CE2 cysts (9.5%), 8 had transitional CE3a
cysts (15.1%), 20 had transitional CE3b cysts (37.7%), and
20 had inactive CE4-CE5 cysts (37.7%). Forty-one patients
(77.4%) had their cysts located in the right segments of the
liver, 5 (9.4%) in the left segments, and 7 (13.2%) in the
fourth segment. Seventeen patients (32.1%) had small-sized
cysts, 27 (50.9%) had medium-sized cysts, and 9 (17.0%)
had large-sized cysts. Serology was positive in 29 patients
(54.7%), negative in 19 patients (35.9%), and doubtful in 5
(9.4%) patients.
3.2. Cytokine Dosages and Associations. IL-10 was unde-
tectable in all 73 serum samples of patients and controls,
while a few sera contained measurable amounts of IFN-γ,4 Clinical and Developmental Immunology
IL-4, and IL-13; percentages of positive samples were 17.8%,
16.4%, and 13.7%, respectively. No statistically signiﬁcant
diﬀerence was found between the percentages of positive
samples for each cytokine and the diﬀerent groups analyzed
(patients/controls, stage, number, location and size of the
cyst, serology, and sex of patients), with the exception
of the association of IL-4 and IL-13 with the cyst stage
(P = 0.010 and P = 0.033, resp.). This was likely due
to higher percentages of positive samples for IL-4 (50%)
and IL-13 (37.5%) in the CE3a-stage group compared to
the other cystic stages. The low number of patients in each
grouppreventedusfromevaluatinganyintergroupstatistical
diﬀerences.
4. Discussion
To date, ultrasound and serology are very useful to diagnose
and monitor the evolution of cystic echinococcosis, but a
marker of activity of the cyst is still lacking. Therefore,
clinical decision making may be challenging, in particular
for those cases that tend to relapse after an initial successful
treatment [1, 17].
It is well known that CE patients generate both Th1 and
Th2 immune responses, which skew towards the Th2 arm
in the chronic phase [7, 18–22]. In this study, we evaluated
the presence of Th1 (IFN-γ) and Th2 cytokines (IL-4, IL-13,
and IL-10) in the sera of patients with diﬀerent cystic stages
according to the WHO-IWGE classiﬁcation of echinococcal
cysts [17]. Unlike previous publications [12, 13, 20], our
resultsshowthatthereisnodiﬀerenceinthepresenceofIFN-
γ, IL-4, and IL-13 in sera of patients compared to negative
controls. This is possibly because cytokines are not speciﬁc
for a particular disease, as they are produced in every Th1-
or Th2-mediated inﬂammatory process. Furthermore, Diaz
et al. [23] recently reviewed the structure of the laminated
layer of the echinococcal cyst and pointed out its possible
role in downregulating both Th1 and Th2 response, thus
allowing parasite survival. This aspect could explain the
low percentage of positive samples containing detectable
amounts of IFN-γ, IL-4, and IL-13. Interestingly, IL-10
could not be detected in any samples analyzed. This could
be due to a sensitivity limit of the ELISA kit employed.
Furthermore, in the literature reviewed by Diaz et al. [23],
IL-10 is expressed by leukocytes in infected hosts, especially
in the immediate vicinity of the parasite. This aspect could
explain the diﬃculty in dosing IL-10 directly in serum
samples.
The comparison of the percentages of positive sam-
ples for each cytokine and the diﬀerent groups analyzed
(patients/controls, stage, number, location, and size of the
cyst, serology, and sex of patients) did not show any
statistically signiﬁcant diﬀerences, with the exception of the
association of IL-4 and IL-13 with the cyst stage. This result
indicates that the percentage of positive samples for both
cytokines is not equal between the diﬀerent cyst stages,
perhaps because of the higher percentage of positive samples
for IL-4 and IL-13 in the CE3a-stage group compared to the
othercysticstages.Furthermore,theseresultsdonotconﬁrm
a previous ﬁnding by our research group, which showed that
the percentage of IL-4-positive samples was higher in CE3b
patientscomparedtoothergroups[14].Alimitation ofthese
studies is the small sample size which is not suﬃcient to
evaluate any intergroup statistical diﬀerences.
Cytokines are immune regulators, which are produced
by many cells and have short half-lives. Therefore, their
measurement in serum is diﬃcult, and results of tests can
be inﬂuenced by several variables, such as sample collection
protocols (sample handling, processing, and storage) and
patient behaviors prior to collection (dietary habits, food
ingestion, physical activity, and stress) [24].
Overall, this investigation showed many limits of serum
cytokine dosage as a marker of biological activity of
echinococcal cysts. Because of low sensitivity and lack of
speciﬁcity of this test, we believe that other ways to evaluate
ex vivo biological activity of the cysts should be explored.
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